Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2009

01-08-2009 | Original Article

Pathological influence of obesity on renal structural changes in chronic kidney disease

Authors: Shigeko Kato, Arifa Nazneen, Yumiko Nakashima, Mohammed S. Razzaque, Tomoya Nishino, Akira Furusu, Noriaki Yorioka, Takashi Taguchi

Published in: Clinical and Experimental Nephrology | Issue 4/2009

Login to get access

Abstract

Background

Role of obesity in renal pathological and structural changes remains poorly investigated, and this study was designed to examine the pathological effects of obesity on renal structural components in patients with chronic kidney diseases (CKD).

Methods

The study subjects were obese (body mass index, BMI ≥ 25 kg/m2) patients with nonglomerulonephritis (non-GN, n = 26), IgA nephropathy (IgAN, n = 19), benign nephrosclerosis (BNS, n = 15), and thin basement membrane disease (TMD, n = 6), and 65 nonobese controls (n = 20, 20, 10, and 15, respectively). Patients were evaluated for glomerular lesions (mesangial proliferation and focal segmental/global glomerulosclerosis), glomerular size, and thickness of glomerular basement membrane (GBM).

Results

Urinary protein was higher in obese non-GN, IgAN, and BNS groups than in the respective controls. Focal segmental glomerulosclerosis (FSGS) lesions were noted in all obesity groups. The glomeruli were larger in size in obese than in nonobese patients of the non-GN and IgAN groups. The glomeruli of nonobese TMD and BNS patients were significantly larger in size than those of nonobese non-GN patients. GBM were thicker in obese than in nonobese patients irrespective of types of glomerular diseases, but only significantly so in non-GN and BNS groups.

Conclusion

In non-GN, IgAN, and BNS, obesity worsens proteinuria and is associated with structural changes such as glomerulomegaly and GBM thickening, similar to changes observed in obesity-related nephropathy. Obesity seems to worsen the renopathological state in CKD.
Literature
1.
go back to reference Hall JE, Henegar JR, Dwyer TM, Liu J, Da Silva AA, Kuo JJ, et al. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther. 2004;11:41–54.CrossRefPubMed Hall JE, Henegar JR, Dwyer TM, Liu J, Da Silva AA, Kuo JJ, et al. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther. 2004;11:41–54.CrossRefPubMed
2.
go back to reference Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.CrossRefPubMed Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.CrossRefPubMed
3.
go back to reference Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006;15:481–6.CrossRefPubMed Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006;15:481–6.CrossRefPubMed
4.
go back to reference Ross WR, McGill JB. Epidemiology of obesity and chronic kidney disease. Adv Chronic Kidney Dis. 2006;13:325–35.CrossRefPubMed Ross WR, McGill JB. Epidemiology of obesity and chronic kidney disease. Adv Chronic Kidney Dis. 2006;13:325–35.CrossRefPubMed
5.
go back to reference Sasatomi Y, Tada M, Uesugi N, Hisano S, Takebayashi S. Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology. 2001;69:113–8.CrossRefPubMed Sasatomi Y, Tada M, Uesugi N, Hisano S, Takebayashi S. Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology. 2001;69:113–8.CrossRefPubMed
6.
go back to reference Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.CrossRefPubMed Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.CrossRefPubMed
7.
go back to reference Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–7.PubMed Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–7.PubMed
8.
go back to reference Kim JJ, Li JJ, Jung DS, Kwak SJ, Ryu DR, Yoo TH, et al. Differential expression of nephrin according to glomerular size in early diabetic kidney disease. J Am Soc Nephrol. 2007;18:2303–10.CrossRefPubMed Kim JJ, Li JJ, Jung DS, Kwak SJ, Ryu DR, Yoo TH, et al. Differential expression of nephrin according to glomerular size in early diabetic kidney disease. J Am Soc Nephrol. 2007;18:2303–10.CrossRefPubMed
9.
go back to reference Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2001;109(Suppl. 2):S424–37.CrossRefPubMed Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2001;109(Suppl. 2):S424–37.CrossRefPubMed
10.
go back to reference Hill GS, Heudes D, Jacquot C, Gauthier E, Bariety J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int. 2006;69:823–31.CrossRefPubMed Hill GS, Heudes D, Jacquot C, Gauthier E, Bariety J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int. 2006;69:823–31.CrossRefPubMed
11.
go back to reference Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, Li LS. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 2006;48:772–9.CrossRefPubMed Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, Li LS. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 2006;48:772–9.CrossRefPubMed
12.
go back to reference Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY. Thin basement membrane nephropathy. Kidney Int. 2003;64:1169–78.CrossRefPubMed Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY. Thin basement membrane nephropathy. Kidney Int. 2003;64:1169–78.CrossRefPubMed
13.
go back to reference Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92.CrossRef Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92.CrossRef
14.
go back to reference Stahl RA, Thaiss F, Wenzel U, Schoeppe W, Helmchen U. A rat model of progressive chronic glomerular sclerosis: the role of thromboxane inhibition. J Am Soc Nephrol. 1992;2:1568–77.PubMed Stahl RA, Thaiss F, Wenzel U, Schoeppe W, Helmchen U. A rat model of progressive chronic glomerular sclerosis: the role of thromboxane inhibition. J Am Soc Nephrol. 1992;2:1568–77.PubMed
15.
go back to reference Osawa G, Kimmelstiel P, Seiling V. Thickness of glomerular basement membranes. Am J Clin Pathol. 1966;45:7–20.CrossRefPubMed Osawa G, Kimmelstiel P, Seiling V. Thickness of glomerular basement membranes. Am J Clin Pathol. 1966;45:7–20.CrossRefPubMed
16.
go back to reference Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant. 2005;20:1320–8.CrossRefPubMed Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant. 2005;20:1320–8.CrossRefPubMed
17.
go back to reference Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, Ma X, et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006;147:44–50.CrossRefPubMed Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, Ma X, et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006;147:44–50.CrossRefPubMed
18.
go back to reference Aunapuu M, Pechter U, Arend A, Suuroja T, Ots M. Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment. Medicina (Kaunas). 2003;39:975–9. Aunapuu M, Pechter U, Arend A, Suuroja T, Ots M. Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment. Medicina (Kaunas). 2003;39:975–9.
19.
go back to reference Tanaka M, Tsujii T, Komiya T, Iwasaki Y, Sugishita T, Yonemoto S, et al. Clinicopathological influence of obesity in IgA nephropathy: comparative study of 74 patients. Contrib Nephrol. 2007;157:90–3.PubMed Tanaka M, Tsujii T, Komiya T, Iwasaki Y, Sugishita T, Yonemoto S, et al. Clinicopathological influence of obesity in IgA nephropathy: comparative study of 74 patients. Contrib Nephrol. 2007;157:90–3.PubMed
20.
go back to reference Serra A, Romero R, Lopez D, Navarro M, Esteve A, Perez N, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73:947–55.CrossRefPubMed Serra A, Romero R, Lopez D, Navarro M, Esteve A, Perez N, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73:947–55.CrossRefPubMed
21.
go back to reference Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, et al. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int. 2007;71:816–21.CrossRefPubMed Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, et al. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int. 2007;71:816–21.CrossRefPubMed
22.
go back to reference Hoy WE, Bertram JF, Denton RD, Zimanyi M, Samuel T, Hughson MD. Nephron number, glomerular volume, renal disease and hypertension. Curr Opin Nephrol Hypertens. 2008;17:258–65.CrossRefPubMed Hoy WE, Bertram JF, Denton RD, Zimanyi M, Samuel T, Hughson MD. Nephron number, glomerular volume, renal disease and hypertension. Curr Opin Nephrol Hypertens. 2008;17:258–65.CrossRefPubMed
23.
go back to reference Hoy WE, Hughson MD, Singh GR, Douglas-Denton R, Bertram JF. Reduced nephron number and glomerulomegaly in Australian Aborigines: a group at high risk for renal disease and hypertension. Kidney Int. 2006;70:104–10.CrossRefPubMed Hoy WE, Hughson MD, Singh GR, Douglas-Denton R, Bertram JF. Reduced nephron number and glomerulomegaly in Australian Aborigines: a group at high risk for renal disease and hypertension. Kidney Int. 2006;70:104–10.CrossRefPubMed
24.
go back to reference Rayat CS, Joshi K, Dey P, Sakhuja V, Minz RW, Datta U. Glomerular morphometry in biopsy evaluation of minimal change disease, membranous glomerulonephritis, thin basement membrane disease and Alport’s syndrome. Anal Quant Cytol Histol. 2007;29:173–82.PubMed Rayat CS, Joshi K, Dey P, Sakhuja V, Minz RW, Datta U. Glomerular morphometry in biopsy evaluation of minimal change disease, membranous glomerulonephritis, thin basement membrane disease and Alport’s syndrome. Anal Quant Cytol Histol. 2007;29:173–82.PubMed
Metadata
Title
Pathological influence of obesity on renal structural changes in chronic kidney disease
Authors
Shigeko Kato
Arifa Nazneen
Yumiko Nakashima
Mohammed S. Razzaque
Tomoya Nishino
Akira Furusu
Noriaki Yorioka
Takashi Taguchi
Publication date
01-08-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0169-3

Other articles of this Issue 4/2009

Clinical and Experimental Nephrology 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine